Combination therapy of Eribulin, Trastuzumab and Pertuzumab for the treatment of patients with previously treated advanced HER2-positive breast cancer.
Phase of Trial: Phase IV
Latest Information Update: 29 Sep 2017
At a glance
- Drugs Eribulin (Primary) ; Pertuzumab; Trastuzumab
- Indications Breast cancer
- Focus Adverse reactions
- 27 Sep 2017 Status changed from active, no longer recruiting to completed.
- 27 Jan 2016 New trial record
- 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium